A previously unknown spinal cord change involving a protein might help expand treatment options for multiple sclerosis, Dr. Fang Liu and her associates at the University of Toronto reported.
The study authors produced a peptide that, in animal models, disrupted a protein that attaches to the neurotransmitter glutamate, a process thought to result in nerve damage and a change in the spinal cord.
“We found that our peptide disrupted this linkage and led to major improvements in neurological functioning,” Dr. Liu said in a statement.
Read the full article here in the Annals of Clinical and Translational Neurology (doi: 10.1002/acn3.182)